ActivBiotics

ActivBiotics develops and sells antibiotics and combination therapies for the treatment of acute and chronic infections. The company’s lead product candidate, Rifalazil, is a proprietary, orally administered antibacterial agent which is in a Phase III clinical trial for the treatment of intermittent claudication associated with peripheral arterial disease. The company’s other product candidate, M40403, is a proprietary small molecule to mimic the function of a naturally occurring enzyme, which plays a role in various inflammatory disease states. It also develops ABI-0043 as a proprietary antibacterial agent for the treatment of complicated skin and skin structure infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. In addition, the company identifies product candidates from its proprietary compound libraries for the treatment of inflammatory diseases and bacterial infections. The company’s superoxide dismutases (SOD) mimetic library consists of approximately 250 small molecules that mimic naturally occurring SOD enzymes.